Altamira Therapeutics (CYTO) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Altamira Therapeutics Ltd. has been notified by Nasdaq of non-compliance with the minimum bid price rule after its shares closed below $1.00 for 30 consecutive days. The company is ineligible for a cure period due to prior reverse stock splits and plans to appeal the decision to maintain its listing. Altamira, known for developing RNA delivery technologies and holding a significant stake in Altamira Medica AG, is awaiting the hearing panel’s decision.
For further insights into CYTO stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue